Attach to Form 990 or Form 990-EZ.
Go to
www.irs.gov/Form990 for instructions and the latest information.
| (i) Name of supported organization | (ii) EIN | (iii) Type of organization (described on lines 1- 10 above (see instructions)) | (iv) Is the organization listed in your governing document? | (v) Amount of monetary support (see instructions) | (vi) Amount of other support (see instructions) | |
|---|---|---|---|---|---|---|
| Yes | No | |||||
|
Total |
||||||
Calendar year
(or fiscal year beginning in)
![]() |
(a) 2019 | (b) 2020 | (c) 2021 | (d) 2022 | (e) 2023 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grant.") .. | ||||||
| 2 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf .... | ||||||
| 3 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | ||||||
| 4 | Total. Add lines 1 through 3 | ||||||
| 5 | The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f) .. | ||||||
| 6 | Public support. Subtract line 5 from line 4. | ||||||
Calendar year
(or fiscal year beginning in)
![]() |
(a) 2019 | (b) 2020 | (c) 2021 | (d) 2022 | (e) 2023 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 7 | Amounts from line 4.. | ||||||
| 8 | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources... | ||||||
| 9 | Net income from unrelated business activities, whether or not the business is regularly carried on.. | ||||||
| 10 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.).. | ||||||
| 11 | Total support. Add lines 7 through 10 | ||||||
Calendar year (or fiscal
year beginning in) ![]() |
(a) 2019 | (b) 2020 | (c) 2021 | (d) 2022 | (e) 2023 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") . | 465,000 | 223,000 | 350,000 | 378,750 | 330,000 | 1,746,750 |
| 2 | Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose | 0 | 0 | 17,494 | 0 | 95 | 17,589 |
| 3 | Gross receipts from activities that are not an unrelated trade or business under section 513 ..... | 0 | 0 | 0 | 0 | 0 | 0 |
| 4 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf... | 0 | 0 | 0 | 0 | 0 | 0 |
| 5 | The value of services or facilities furnished by a governmental unit to the organization without charge | 0 | 0 | 0 | 0 | 0 | 0 |
| 6 | Total. Add lines 1 through 5 | 465,000 | 223,000 | 367,494 | 378,750 | 330,095 | 1,764,339 |
| 7a | Amounts included on lines 1, 2, and 3 received from disqualified persons | 0 | 0 | 0 | 0 | 0 | 0 |
| b | Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year. | 0 | 0 | 0 | 0 | 0 | 0 |
| c | Add lines 7a and 7b.. | 0 | 0 | 0 | 0 | 0 | 0 |
| 8 | Public support. (Subtract line 7c from line 6.) | 1,764,339 | |||||
Calendar year
(or fiscal year beginning in)
![]() |
(a) 2019 | (b) 2020 | (c) 2021 | (d) 2022 | (e) 2023 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 9 | Amounts from line 6... | 465,000 | 223,000 | 367,494 | 378,750 | 330,095 | 1,764,339 |
| 10a | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources.. | 725 | 730 | 166 | 46 | 44 | 1,711 |
| b | Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975. | 0 | 0 | 0 | 0 | 0 | 0 |
| c | Add lines 10a and 10b. | 725 | 730 | 166 | 46 | 44 | 1,711 |
| 11 | Net income from unrelated business activities not included on line 10b, whether or not the business is regularly carried on. | 0 | 0 | 0 | 0 | 0 | 0 |
| 12 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.) .. | 0 | 0 | 0 | 0 | 0 | 0 |
| 13 | Total support. (Add lines 9, 10c, 11, and 12.).. | 465,725 | 223,730 | 367,660 | 378,796 | 330,139 | 1,766,050 |
| Section A - Adjusted Net Income | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Net short-term capital gain | 1 | ||||
| 2 | Recoveries of prior-year distributions | 2 | ||||
| 3 | Other gross income (see instructions) | 3 | ||||
| 4 | Add lines 1 through 3 | 4 | ||||
| 5 | Depreciation and depletion | 5 | ||||
| 6 | Portion of operating expenses paid or incurred for production or collection of gross income or for management, conservation, or maintenance of property held for production of income (see instructions) | 6 | ||||
| 7 | Other expenses (see instructions) | 7 | ||||
| 8 | Adjusted Net Income (subtract lines 5, 6 and 7 from line 4) | 8 | ||||
| Section B - Minimum Asset Amount | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Aggregate fair market value of all non-exempt-use assets (see instructions for short tax year or assets held for part of year): | 1 | ||||
| a | Average monthly value of securities | 1a | ||||
| b | Average monthly cash balances | 1b | ||||
| c | Fair market value of other non-exempt-use assets | 1c | ||||
| d | Total (add lines 1a, 1b, and 1c) | 1d | ||||
| e |
Discount claimed for blockage or other factors (explain in detail in Part VI): |
|||||
| 2 | Acquisition indebtedness applicable to non-exempt use assets | 2 | ||||
| 3 | Subtract line 2 from line 1d | 3 | ||||
| 4 | Cash deemed held for exempt use. Enter 0.015 of line 3 (for greater amount, see instructions). | 4 | ||||
| 5 | Net value of non-exempt-use assets (subtract line 4 from line 3) | 5 | ||||
| 6 | Multiply line 5 by 0.035 | 6 | ||||
| 7 | Recoveries of prior-year distributions | 7 | ||||
| 8 | Minimum Asset Amount (add line 7 to line 6) | 8 | ||||
| Section C - Distributable Amount | Current Year | |||||
| 1 | Adjusted net income for prior year (from Section A, line 8, Column A) | 1 | ||||
| 2 | Enter 85% of line 1 | 2 | ||||
| 3 | Minimum asset amount for prior year (from Section B, line 8, Column A) | 3 | ||||
| 4 | Enter greater of line 2 or line 3 | 4 | ||||
| 5 | Income tax imposed in prior year | 5 | ||||
| 6 | Distributable Amount. Subtract line 5 from line 4, unless subject to emergency temporary reduction (see instructions) | 6 | ||||
| Section D - Distributions | Current Year | |
|---|---|---|
| 1 Amounts paid to supported organizations to accomplish exempt purposes | 1 | |
|
2
Amounts paid to perform activity that directly furthers exempt purposes of supported organizations, in excess of income from activity |
2 | |
| 3 Administrative expenses paid to accomplish exempt purposes of supported organizations | 3 | |
| 4 Amounts paid to acquire exempt-use assets | 4 | |
| 5 Qualified set-aside amounts (prior IRS approval required - provide details in Part VI) | 5 | |
| 6 Other distributions (describe in Part VI). See instructions | 6 | |
| 7Total annual distributions. Add lines 1 through 6. | 7 | |
|
8
Distributions to attentive supported organizations to which the organization is responsive (provide details in Part VI). See instructions |
8 | |
| 9 Distributable amount for 2023 from Section C, line 6 | 9 | |
| 10 Line 8 amount divided by Line 9 amount | 10 | |
| Section E - Distribution Allocations (see instructions) |
(i) Excess Distributions |
(ii) Underdistributions Pre-2023 |
(iii) Distributable Amount for 2023 |
|
|---|---|---|---|---|
| 1 Distributable amount for 2023 from Section C, line 6 | ||||
|
2
Underdistributions, if any, for years prior to 2023 (reasonable cause required-- explain in Part VI).
See instructions. |
||||
| 3 Excess distributions carryover, if any, to 2023: | ||||
| a From 2018....... | ||||
| b From 2019....... | ||||
| c From 2020....... | ||||
| d From 2021....... | ||||
| e From 2022....... | ||||
| fTotal of lines 3a through e | ||||
| g Applied to underdistributions of prior years | ||||
| h Applied to 2023 distributable amount | ||||
|
i
Carryover from 2018 not applied (see instructions) |
||||
| j Remainder. Subtract lines 3g, 3h, and 3i from line 3f. | ||||
| 4Distributions for 2023 from Section D, line 7: | ||||
| $ | ||||
| a Applied to underdistributions of prior years | ||||
| b Applied to 2023 distributable amount | ||||
| c Remainder. Subtract lines 4a and 4b from line 4. | ||||
|
5
Remaining underdistributions for years prior to 2023, if any. Subtract lines 3g and 4a from line 2. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
6
Remaining underdistributions for 2023. Subtract lines 3h and 4b from line 1. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
7 Excess distributions carryover to 2024. Add lines 3j and 4c. |
||||
| 8 Breakdown of line 7: | ||||
| a Excess from 2019..... | ||||
| b Excess from 2020..... | ||||
| c Excess from 2021..... | ||||
| d Excess from 2022..... | ||||
| e Excess from 2023..... | ||||
| Facts And Circumstances Test |
|---|
| Return Reference | Explanation |
|---|---|
| Part III - Line 12 | | Year:, Amount:, Description:| 2019, , | 2020, | 2021, | 2022, | 2023, | |
| Software ID: | |
| Software Version: |
| Return Reference | Explanation |
|---|---|
| Part VI, Line 6 | Manufacturer members and blood service organizations are the supporting members of this corporation. Each organization pays dues to participate in the scientific discussions of the scientific members who must apply for membership. There are two classes of members in each category voting and non-voting. |
| Part VI, Line 7a | Explanation Manufacturer members and blood service organizations are the supporting members of this corporation. Each organization pays dues to participate in the scientific discussions of the scientific members who must apply for membership. There are two classes of members in each category voting and non-voting. The Executive Committee which operates as the corporations Board of Directors is chosen by the President per the corporate bylaws. The President is elected by the voting members of the membership every four years. The immediate past-president serves as the Treasurer for that term. The President serves as the corporations Secretary. |
| Part VI, Line 12c | The corporation has had a conflict of interest policy in effect since its inception. This requires all scientific members not just directors and officers to declare significant interests that may have an effect on the real or perceived objectivity of their statements and presentations. These are completed and reviewed annually and distributed as part of the materials for each meeting. As this scientific community is a small one and its members are well-known to each other any failure to forthrightly state ones connection with another enterprise would be readily apparent and the statement of conflicts called into question.In addition the state of New Hampshire requires a separate statement with stricter limits from all directors regarding financial dealings with the organization. |
| Part VI, Line 15 | The contract for the Executive Director is reviewed by the Board of Directors very four years. Compensation is determined on similar positions within the Transfusion Medicine industry along with the duties performed. The Directors and Officers are not compensated only reimbursed for travel and other corporate business-related expenses. |
| Part VI, line 9 | | Name of the person:, Address of the person:| Zbigniew M Szczepiorkowski MD PhD, One Medical Center Drive, One Medical Center Drive, One Medical Center Drive, NH, 03756| Michael F Murphy MD, 88 Lonsdale Roard, 88 Lonsdale Roard, 88 Lonsdale Roard, OX, UK, OX27ER| Meghan Delaney DO MPH, Childrens National Hospital, Childrens National Hospital, Childrens National Hospital, DC, 20010| Simon Stanworth MA FRCP PhD FRCPath, The John Radcliffe Hospital, The John Radcliffe Hospital, The John Radcliffe Hospital, OX, UK, OX39BQ| Denese Marks PhD, 17 ORiordan Street, 17 ORiordan Street, 17 ORiordan Street, NSW,AS, 2015| Rebecca Cardigan PhD, NHSBT, NHSBT, NHSBT, CB, UK, CB2 2PT| David McKenna MD, University of Minnesota, University of Minnesota, University of Minnesota, MN, 55108| David Stroncek MD, National Institutes of Health, National Institutes of Health, National Institutes of Health, MD, 20892| Ralph Vassallo MD, Vitalant, 9305 EVia de Ventura, Vitalant, AZ, 85258| Marc Germain MD PhD, HemaQuebec, HemaQuebec,HemaQuebec, QC, CA, G1V 5C3 |
| Part III Line 4 | | Explanation:| Cognasse F et al. Biomedical Excellence for Safer Transfusion BEST Collaborative. Assessment of the soluble proteins HMGB1 CD40L and CD62P during various platelet preparation processes and the storage of platelet concentrates: The BEST Collaborative study. Transfusion. 2023 Jan. 631:217-228. Lu W et al. Biomedical Excellence for Safer Transfusion BEST Collaborative. Assessment of the soluble proteins HMGB1 CD40L and CD62P during various platelet preparation processes and the storage of platelet concentrates: The BEST Collaborative study. Transfusion. 2023 Jan. 631:217-228. Cloutier M et al. Biomedical Excellence for Safer Transfusion BEST Collaborative. Quality assessment of red blood cell concentrates from blood donors at the extremes of the age spectrum: The BEST collaborative study. Transfusion. 2023 Jun 30. doi: 10.1111 trf.17471. Zeller et al. BEST Collaborative. Optimizing Informed Consent Discussions: Developing a Narrative for Transfusion Consent. Transfus Med Rev. 2023 Sep 9;150757. doi: 10.1016 j.tmrv.2023.150757. Kaufman RM et al.Biomedical Excellence for Safer Transfusion Collaborative.Risk factors for T-cell lymphopenia in frequent platelet donors: The BEST collaborative study. Transfusion. 2023 Nov;6311:2072-2082. Thibodeaux SR et al. Biomedical Excellence for Safer Transfusions BEST Collaborative. Assessing deviations for HPCs obtained during COVID-19 ADHOC: Evaluating impact of the COVID-19 pandemic on cellular therapy products and processes the BEST collaborative study. Transfusion. 2023 Apr;634:782-790. Shaz BH et al. for Biomedical Excellence for Safer Transfusion BEST collaborative study. Local manufacturing processes contribute to variability in human mesenchymal stromal cell expansion while growth media supplements contribute to variability in gene expression and cell function: a Biomedical Excellence for Safer Transfusion BEST collaborative study. Cytotherapy. 2023 Dec 2:S1465-32492301101-5. |
| Software ID: | |
| Software Version: |